A prospective, multicenter study of bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory iMCD

References

• Cabot RC, Castleman B, Towne VW. CASE records of the Massachusetts general hospital weekly clinicopathological exercises: case 40011. N Engl J Med. 1954;250(1):26–30.
   PubMedGoogle Scholar
• Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric castleman disease. Blood. 2017;129(12):1646–1657.
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255–2273.
   PubMed Web of Science ®Google Scholar
• Zhang X, Rao H, Xu X, et al. Clinical characteristics and outcomes of castleman disease: a multicenter study of 185 Chinese patients. Cancer Sci. 2018;109(1):199–206.
   PubMed Web of Science ®Google Scholar
• Melikyan AL, Egorova EK, Kovrigina AM, et al. [Clinical and morphological features of different types of Castleman's disease]]. Ter Arkh. 2015;87(7):64–71.
   PubMed Web of Science ®Google Scholar
• Seo S, Yoo C, Yoon DH, et al. Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman’s disease: a single medical center experience. Blood Res. 2014;49(4):253–258.
   PubMedGoogle Scholar
• van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966–974.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric castleman disease. Blood. 2018;132(20):2115–2124.
   PubMed Web of Science ®Google Scholar
• Yuan ZG, Dun XY, Li YH, et al. Treatment of multicentric Castleman’s disease accompanying multiple myeloma with bortezomib: a case report. J Hematol Oncol. 2009;2:19.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Richardson PG, Hideshima T, et al. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005;23(3):630–639.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang W, Kang WY, et al. Bortezomib and dexamethasone as first-line therapy for a patient with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M protein and skin changes syndrome complicated by renal failure. Leuk Lymphoma. 2012;53(12):2527–2529.
   PubMed Web of Science ®Google Scholar
• Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions and long-term outcome. Blood. 2003;101(7):2496–2506.
   PubMed Web of Science ®Google Scholar
• Li J, Zhou DB, Huang Z, et al. Clinical characteristics and long-term outcome of patients with POEMS syndrome in China. Ann Hematol. 2011;90(7):819–826.
   PubMed Web of Science ®Google Scholar
• Hess G, Wagner V, Kreft A, et al. Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease. Br J Haematol. 2006;134(5):544–545.
   PubMed Web of Science ®Google Scholar
• Lin Q, Fang B, Huang H, et al. Efficacy of bortezomib and thalidomide in the recrudescent form of multicentric mixed-type Castleman’s disease. Blood Cancer J. 2015;5(3):e298.
   PubMedGoogle Scholar
• Xia P, Zhang L, Zou M, et al. Acute kidney injury caused by TAFRO syndrome in a Chinese patient: efficacy of long-term corticosteroids combined with bortezomib and Cyclophosphamide. Kidney Blood Press Res. 2020;45(4):623–630.
   PubMed Web of Science ®Google Scholar
• Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12(5):431–440.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhao AL, Duan MH, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric castleman disease. Blood. 2019;133(16):1720–1728.
   PubMed Web of Science ®Google Scholar
• van Rhee F, Stone K. Storming the castle with TCP. Blood. 2019;133(16):1697–1698.
   PubMed Web of Science ®Google Scholar
• Igawa T, Sato Y. TAFRO syndrome. Hematol Oncol Clin North Am. 2018;32(1):107–118.
   PubMed Web of Science ®Google Scholar
• Lassalle A, Thomaré P, Fronteau C, et al. Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study. Ann Oncol. 2016;27(2):314–318.
   PubMed Web of Science ®Google Scholar
• Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23(7):1337–1341.
   PubMed Web of Science ®Google Scholar
• Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol. 2007;138(3):330–337.
   PubMed Web of Science ®Google Scholar
• Shen KN, Zhang CL, Tian Z, et al. Bortezomib-based chemotherapy reduces early mortality and improves outcomes in patients with ultra-high-risk light-chain amyloidosis: a retrospective case control study. Amyloid. 2019;26(2):66–73.
   PubMed Web of Science ®Google Scholar
• Kim I, Moon SO, Kim SH, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem. 2001;276(10):7614–7620.
   PubMed Web of Science ®Google Scholar
• Morra DE, Pierson SK, Shilling D, et al. Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data. Br J Haematol. 2019;184(2):232–241.
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, Langan RA, Japp AS, et al. Identifying and targeting pathogenic PI3K/AKT/mTOR signaling in IL-6-blockade-refractory idiopathic multicentric Castleman disease. J Clin Invest. 2019;129(10):4451–4463.
   PubMed Web of Science ®Google Scholar
• Zhang S, Kulkarni AA, Xu B, et al. Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. Blood Cancer J. 2020;10(3):33.
   PubMed Web of Science ®Google Scholar